Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
| FRBRX Fund | USD 141.38 6.06 4.11% |
Slightly above 61% of Franklin Biotechnology's investor base is looking to short. The analysis of overall sentiment of trading Franklin Biotechnology Discovery mutual fund suggests that many investors are alarmed at this time. Franklin Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Franklin Biotechnology's earnings reports, geopolitical events, and overall market trends.
Franklin |
PARIS - French healthcare company Sanofi has agreed to buy the drug development project INBRX-101 from its parent company Inhibrx Inc for around 2.2 billion, the companies said on Tuesday. As part of...
Read at streetinsider.com
 |
Franklin Biotechnology Fundamental Analysis
We analyze Franklin Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Franklin Biotechnology is currently under evaluation in number of employees among similar funds. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Franklin Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Franklin Biotechnology mutual fund to make a market-neutral strategy. Peer analysis of Franklin Biotechnology could also be used in its relative valuation, which is a method of valuing Franklin Biotechnology by comparing valuation metrics with similar companies.
Peers
Franklin Biotechnology Related Equities
| SBQAX | Americafirst Large | 0.49 |
| ||
| TWQZX | Transamerica Large | 0.59 |
| ||
| VAAGX | Virtus Nfj | 0.66 |
| ||
| DOXGX | Dodge Cox | 0.67 |
| ||
| GMLVX | Guidemark Large | 1.37 |
| ||
| PCLVX | Pace Large | 2.54 |
| ||
| LMISX | Qs Large | 3.27 |
|
Other Information on Investing in Franklin Mutual Fund
Franklin Biotechnology financial ratios help investors to determine whether Franklin Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Franklin with respect to the benefits of owning Franklin Biotechnology security.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |